Eli Lilly and Co. has won U.S. regulatory approval to market its slow-selling osteoporosis drug Forteo for a new use, Lilly announced today. Lilly can now promote Forteo as a therapy for men and women who regularly take medicines called glucocorticoids for rheumatory arthritis or obstructive lung disease. Sustained use of glucocorticoids cause bone fractures in half the patients taking them, or slightly more than 1 million Americans. Forteo sales have stalled this year, totaling $391 million through the end of June. The U.S. Food and Drug Administration approved the new use after Lilly submitted data showing that Forteo increased bone-mineral density in patients with glucocorticoid-induced osteoporosis by 7.2 percent in the spine, 3.6 percent in the hips and 3.7 percent in the femur.